| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. .png)
|
|
Today’s Big NewsJan 30, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Kevin Dunleavy Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June 2026 after leading Japan’s largest drugmaker for 11 years. |
|
|
|
By Nick Paul Taylor Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. |
By Nick Paul Taylor Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, Principia Biopharma and Synthorx. |
By Fraiser Kansteiner During its first full year on the market, Sanofi's respiratory syncytial virus antibody Beyfortus easily broke the $1 billion sales threshold. The drug still has plenty of room left to grow in places like the U.S., Sanofi executives said on an analyst call Thursday. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Angus Liu After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. Still, questions continue to swirl about an evolving market showdown with Regeneron’s rival drug. |
By Conor Hale Headquartered in Valencia, Spain, Quibim has already collected several international green lights and now aims to expand into the U.S. market. |
By Nick Paul Taylor Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its clinical data package. |
By James Waldron Cargo Therapeutics is lightening its load, jettisoning 50% of its employees along with the CAR-T company’s lead candidate in the wake of weak durability and serious side effects. |
By Kevin Dunleavy For "ethical" reasons, Merck has halted the phase 3 HYPERION trial of its pulmonary arterial hypertension (PAH) treatment Winrevair after reviewing positive interim results from another study and evaluating the drug’s overall clinical program. All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said. |
By James Waldron Shionogi’s respiratory syncytial virus antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. |
By Darren Incorvaia An antibody that can bind to many different types of influenza virus prevented macaques from getting seriously sick, and dying, from a highly pathogenic strain of H5N1 bird flu. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
